Valuation: Omeros Corporation

Market Cap 1.26B 1.09B 1.03B 940M 1.76B 120B 1.76B 12.32B 4.77B 61.09B 4.72B 4.61B 196B P/E 2026 *
19.5x
P/E 2027 * 17.3x
Enterprise Value 1.26B 1.09B 1.03B 940M 1.76B 120B 1.76B 12.32B 4.77B 61.09B 4.72B 4.61B 196B EV / Sales 2026 *
9.99x
EV / Sales 2027 * 6.35x
Free-Float
95.92%
Yield 2026 *
-
Yield 2027 * -
1 day+6.57%
1 week-1.43%
Current month-2.47%
1 month+5.56%
3 months+90.09%
6 months+62.60%
Current year+6.70%
1 week 16.5
Extreme 16.5001
18.98
1 month 16.5
Extreme 16.5001
19.65
Current year 6.7
Extreme 6.7023
19.65
1 year 4.05
Extreme 4.05
19.65
3 years 0.92
Extreme 0.92
19.65
5 years 0.92
Extreme 0.92
19.65
10 years 0.92
Extreme 0.92
27.09
Manager TitleAgeSince
Chief Executive Officer 67 16/06/1994
Director of Finance/CFO 62 30/06/2024
Chief Tech/Sci/R&D Officer 70 01/11/2019
Director TitleAgeSince
Chairman 67 16/06/1994
Director/Board Member 86 01/01/1995
Director/Board Member 72 01/01/1995
Date Insider Type Main position Quantity % Market Cap. Importance
31/8/26 Exercice

General Counsel

75,000 0.1036%
27/8/26 Exercice

Director

30,000 0.0415%
24/8/26 Exercice

Chief Financial Officer

2,718 0.0038%
Change 5-day change 1-year change 3-year change Capi.($)
+6.72%-1.43%+351.35%+504.79% 1.26B
+1.76%+3.62%+49.92%+101.12% 69.69B
+2.29%+1.43%+38.39%+77.80% 61.24B
+0.61%-3.37%-15.05%+363.24% 26.77B
+0.32%+2.58%+29.26%+14.12% 26.12B
+3.40%+2.89%+1.05%-9.04% 24.07B
+1.49%+7.73%+26.85%-13.79% 20.39B
-0.83%-11.15%+169.70%+295.44% 15.72B
+2.08%+0.92%+43.32%+171.48% 14.07B
+0.17%-4.07%-9.71%+484.05% 14.03B
Average +1.76%-2.12%+68.51%+198.92% 27.34B
Weighted average by Cap. +1.54%+0.15%+37.85%+131.28%

Financials

2026 *2027 *
Net sales 126M 109M 104M 94.07M 176M 12.03B 177M 1.23B 477M 6.11B 472M 461M 19.57B 198M 172M 163M 148M 277M 18.94B 278M 1.94B 751M 9.63B 743M 727M 30.82B
Net income 63.3M 55.13M 52.18M 47.41M 88.57M 6.06B 89.01M 622M 240M 3.08B 238M 233M 9.86B 79.47M 69.22M 65.51M 59.52M 111M 7.61B 112M 780M 302M 3.87B 299M 292M 12.38B
Net Debt - -
Logo Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
Employees
175
Date Price Change Volume
18/09/26 USD 18.33 +5.71% 1,730,458
16/09/26 USD 17.34 +0.99% 2,108,105
15/09/26 USD 17.17 -1.66% 1,655,628
14/09/26 USD 17.46 -4.49% 1,691,497
11/09/26 USD 18.28 -1.67% 1,014,308
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
17.34USD
Average target price
33.00USD
Spread / Average Target
+90.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OMER Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!